Highlights Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
71.71 ^USD	+0.27%		+5.61%	-9.90%

Apr. 02	Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	MT
Apr. 01	Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	Apr. 01	CI
Axsome Therapeutics Says Survey Shows Narcolepsy Symptoms Persist Despite Treatment	Mar. 25	MT
Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	Mar. 25	CI
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial	Mar. 25	RE
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in the SYMPHony Phase 3 Trial in Narcolepsy	Mar. 25	CI
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	Mar. 19	CI
Axsome Therapeutics Q4 Net Loss Widens, Revenue Rises; Shares Drop	Feb. 20	MT
Axsome Therapeutics Q4 Net Loss Widens, Revenue Rises	Feb. 20	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Reports Q4 Revenue $71.5M, vs. Street Est of $69M	Feb. 20	MT
Axsome Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
Axsome Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 20	CI
North American Morning Briefing : Earnings Back in -2-	Feb. 20	DJ
Axsome Therapeutics Q3 Net Loss Widens, Revenue Rises	Nov. 06	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q3 Revenue $57.8M, vs. Street Est of $54.9M	Nov. 06	MT
Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference	23-10-24	CI
Axsome Therapeutics' Q2 Net Loss Widens, Revenue Increases	23-08-07	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q2 Revenue $46.7M, vs. Street Est of $41M	23-08-07	MT
Axsome Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder in Adults	23-07-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Highlights

Filters